StageZero Life Sciences Ltd. (OTCMKTS:SZLSF – Get Rating) saw a significant decline in short interest in February. As of February 15th, there was short interest totalling 3,400 shares, a decline of 46.9% from the January 31st total of 6,400 shares. Based on an average daily volume of 10,400 shares, the short-interest ratio is presently 0.3 days.
StageZero Life Sciences Price Performance
OTCMKTS SZLSF remained flat at $0.10 on Thursday. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.08 and a quick ratio of 0.04. The company's 50 day moving average price is $0.05 and its 200 day moving average price is $0.06. StageZero Life Sciences has a 1-year low of $0.04 and a 1-year high of $0.16.
Get
StageZero Life Sciences alerts:
About StageZero Life Sciences
(Get Rating)
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K.
See Also
- Get a free copy of the StockNews.com research report on StageZero Life Sciences (SZLSF)
- Hormel Hits 2-Year Low, And The Dip Gets Bought
- Here's Why Ross Could Soon Be Hitting All Time Highs
- The Bottom Is In For Salesforce.com
- It's Time For A Fresh Look At The Kroger Co.
- West Fraser's Earnings Scream Timber, Outlook Says Buy
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
StageZero生命科學有限公司(OTCMKTS:SZLSF-GET Rating)看到空頭股數在2月份出現了顯著下降。截至2月15日,空頭股數共有3400股,較1月31日的6400股下降了46.9%。以日均成交量一萬零四百股計算,短息比率目前為零點三天。
StageZero生命科學性價比
OTCMKTS SZLSF週四持平於0.10美元。該公司的債務權益比為0.44,流動比率為0.08,速動比率為0.04。該公司的50日移動均線價格為0.05美元,其200日移動均線價格為0.06美元。StageZero生命科學的一年低點為0.04美元,一年高位為0.16美元。
到達
StageZero生命科學警報:
關於StageZero生命科學
(獲取評級)
StageZero生命科學有限公司致力於專利分子診斷測試的開發和商業化,用於檢測疾病和個性化健康管理,重點是癌症相關適應症。其產品包括哨兵原理和科隆哨兵。該公司是由劉忠欽和K。
另請參閱
- 免費獲取StockNews.com關於StageZero生命科學(SZLSF)的研究報告
- 霍梅爾跌至兩年低點,Dip被收購
- 以下是羅斯可能很快就會創下歷史新高的原因
- Salesforce.com的底部已經到了
- 是時候重新審視克羅格公司了。
- West Fraser‘s盈利尖叫木材,前景稱買入
接受StageZero生命科學日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對StageZero生命科學和相關公司的最新新聞和分析師評級的每日簡要摘要。